<DOC>
	<DOCNO>NCT01901666</DOCNO>
	<brief_summary>CML myeloproliferative disorder define presence Philadelphia chromosome , arise reciprocal translocation gene chromosomes 9 22.It rare childhood account 2-3 % leukemias childhood . BCR-ABL gene Philadelphia chromosome result 210kd fused BCR-ABL protein constitutive tyrosine kinase activity , subsequent activation cytoplasmic nuclear signal transduction pathway include STAT , RAS , JUN , MYC , phosphatidylinositol-3 kinase . The ultimate result activation myeloid proliferation differentiation suppress apoptosis . Children present high WBC count , otherwise presentation nearly identical adult . Current treatment include tyrosine kinase inhibitor ( TKI ) allogeneic stem cell transplant ( SCT ) .Imatinibmesylate inhibits tyrosine kinase ( TK ) activity BCR-ABL1 several related TKs , include c-kit platelet-derived growth factor receptor ( PDGFR ) . Development tyrosine kinase inhibitor ( TKI ) therapy revolutionizedtreatment CML . Imatinib second generation TKIs ( dasatinib nilotinib ) become standard front-line therapy forchildren adult CML also important componentsof therapy Ph+ acute lymphoblastic leukemia ( ALL ) . TKIs administer orally cause number side effect include fatigue , hypertension , rash , impair wound healing , myelosuppression , diarrhea . The overall toxicity TKIs , less life-threatening conventional cytotoxic chemotherapy , nevertheless common , may require dose reduction.Recently , propose endocrine-related side effect agent include alteration thyroid function , bone metabolism , linear growth , gonadal function , fetal development , glucose metabolism adrenal function . Growth impairment one major adverse effect long-term imatinib treatment child CML . Multiple case report demonstrate growth retardation child onimatinib.Imatinibmesylate inhibits TK activity BCR-ABL1 several related TKs , include c-kit theplatelet-derived growth factor receptor ( PDGFR ) . It isthe inhibition TK activity non-BCR-ABL site couldbe likely cause adverse effect growth . Severalstudies adult suggest inhibition c-kit , c-fms , PDGF receptor result modulation bone metabolism . Other report focus disturbance growth hormone ( GH ) axis mechanism growth impairment . Receptor non receptor TK express multiple level GH-IGF-1 axis include GHRH-R , GH-R IGF-1R . Inhibition TKs TKI , one level , might result growth impairment . Various study available show Imainib therapy may cause short stature child prolong treatment exact mechanism occur still clear . Further , treatment modality try far , short stature child . So , purpose study study GH-IGF1 axis child administer GH therapy GH deficienct child remission .</brief_summary>
	<brief_title>Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia ( CML ) In Remission</brief_title>
	<detailed_description>AIMS AND OBJECTIVES : - To study GH-IGF1 axis child CML short stature follow Imatinib therapy . - To administer growth hormone therapy child CML Imatinib remission GH deficiency . STUDY DESIGN : It interventional , non-randomized study . STUDY GROUP : one NUMBER OF PATIENTS : 20 ELIGIBILITY CRITERIA : CML patient Imatinib therapy 6 month remission include study : - Severe short stature ( height SDS &lt; -3 SD ) - Severe growth deceleration ( height velocity SDS &lt; -2 SD 12 month ) - Height &lt; -2 SD height velocity &lt; -1.0 SD 12 month - Height &lt; -1.5 SD height velocity &lt; -1.5 SD 2 year EXCLUSION CRITERIA : - Patients coexist systemic illness ( e.g . kidney disease , liver disease , celiac disease ) - Patients CML receive Imatinib therapy prescribed . ( e.g . poor compliance ) MATERIALS AND METHODS : Once eligibility criterion confirm , write informed consent , follow parameter assess : - Chronological age - Height - Height age - Height SDS - Target height - Body proportion - Weight - Weight age Following investigation do patient : - Complete blood count peripheral smear . - Liver function test - Renal function test - Calcium , phosphate , ALP , albumin . - Fasting Blood glucose - Thyroid function test ( T4 , TSH ) - Serum Cortisol - Serum Prolactin - Serum Follicular stimulate hormone ( FSH ) Luteinizing hormone ( LH ) - Serum Testosterone - Serum Estrogen - Serum IgA anti-tTG antibody - Serum IGF-1 . - Serum IGFBP-3 . - X-Ray left hand wrist - MRI Brain focus pituitary hypothalamic region . Two dynamic growth hormone provocation , GHRH + Arginine andGlucagon test perform patient cause short stature.Minimum gap one week keep two GHstimulationtests.Priming do prior GH stimulation test . IGF-1 generation test perform patients.Minimum gap one week keep betweenGH stimulation IGF-1 generation test . X-ray leave hand wrist bone age sexual maturity rating ( SMR ) Tanners scale perform patient . All GH deficient patient bone age &lt; 14 year treat GH therapy one year . 0.3mg/kg/week GH seven divide dos give subcutaneously . Serum IGF-1 measure 4weekly GH dose titrate till S.IGF-1 mid-normal range every 3 month . Patients monitor side effect GH therapy Growth parameter , Serum T4 , TSH complete blood count assess every 3 months.Cytogenetic molecular remission assess completion GH therapy .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Dwarfism</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>CML patient Imatinib therapy 6 month remission include study 1. severe short stature ( height SDS &lt; 3 SD ) 2. severe growth deceleration ( height velocity &lt; 2 SD 12 month ) 3 . Height &lt; 2 SD height velocity &lt; 1.0 SD 12 month 4 . Height &lt; 1.5 SD height velocity &lt; 1.5 SD 2 year 1 . Patients coexist systemic illness ( e.g . kidney disease , liver disease , celiac disease ) . 2 . Patients CML receive Imatinib therapy prescribed ( poor compliance ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>growth hormone , Chronic Myelogenous Leukemia , Imatinib , serum IGF-1</keyword>
</DOC>